基因组前列腺评分和治疗选择在有利的中等风险前列腺癌中
Eric Margolis1, Benjamin H Lowentritt2, Christopher M Pieczonka3
1Hackensack Meridian School of Medicine Nutley NJ USA.
BJUI compass
|March 19, 2025
概括
31%的中等风险前列腺癌患者选择积极监测 (AS). 17基因基因组前列腺评分 (GPS) 和百分比阳性核心显著影响这些患者的AS选择.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 积极监测 (AS) 是低风险前列腺癌 (PCa) 的管理策略.
- 有利的中期风险 (FIR) PCa患者可能是AS的候选人.
- 17基因的基因组前列腺分数 (GPS) 试验为PCa提供了风险分层.
研究的目的:
- 在NCCN FIR PCa患者中确定与AS使用相关的因素.
- 评估GPS测试对AS决策的影响.
- 分析GPS结果与AS选择之间的关系.
主要方法:
- 对324名接受GPS检测的FIR PCa患者进行了回顾性分析.
- 后勤回归模型 (单变量和多变量) 来评估AS选择预测因素.
- 计算附属系统选择比例和置信区间.
主要成果:
- 31%的患者选择AS,较高的GPS得分与较低的AS使用相关.
- GPS结果 (0-19: 58%, 20-40: 27%, 41-100: 6%) 和正核的百分比是AS选择的重要预测因素.
- 多变量分析证实GPS和百分比正核是重要的因素.
结论:
- GPS测定结果和百分比阳性核与FIR PCa中的AS使用有关.
- 这些因素有助于中等风险PCa中AS的临床决策.
- 高AS持久性 (91%在12个月) 表明患者和医生对AS选择的信心.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...